20/20 Biolabs, Inc. Common Stock (AIDX)vsBoston Scientific Corp (BSX)
AIDX
20/20 Biolabs, Inc. Common Stock
$1.64
-17.59%
HEALTHCARE · Cap: $20.59M
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 982523% more annual revenue ($20.07B vs $2.04M). BSX leads profitability with a 14.4% profit margin vs -1.6%. BSX earns a higher WallStSmart Score of 63/100 (C+).
AIDX
Avoid18
out of 100
Grade: F
BSX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
15.8% revenue growth
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Trading at 164.0x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Revenue Growth. Revenue growth of 15.8% demonstrates continued momentum.
Bull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Key Dynamics to Monitor
BSX carries more volatility with a beta of 0.70 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (63/100 vs 18/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (ticker: AIDX) is a biotechnology company focused on providing innovative solutions for genomic research and diagnostics. The company specializes in delivering advanced laboratory services that enhance the accuracy and efficiency of genetic testing, catering to both clinical and research markets. With a commitment to leveraging cutting-edge technologies, 20/20 Biolabs aims to redefine the standards of molecular diagnostics and contribute significantly to the advancement of personalized medicine. As the demand for genomic data continues to rise, the company's strategic initiatives position it well for growth in this rapidly evolving sector.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?